The Effects of HER2 Receptor Signaling on Human Brown Fat Activity
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this observational study is to investigate the significance of the HER2 receptor for brown fat activity in humans. Our preliminary data clearly demonstrates that the ErbB signaling pathway, which includes the HER2 receptor, strongly promotes development and function of cultured human BAT cells. The HER2 receptor is a part of the ErbB signaling pathway, and antibodies against thee HER2 receptor are a part of the standard treatment for HER2-positive breast cancer. Therefore, the hypothesis is that the activity of brown fat will be reduced in patients treated with HER2 blocking antibody compared to patients who are not treated with HER2 blocking antibody. The present study simply takes advantage of the treatment protocol to explore the contribution of the HER2 receptor in the development of brown adipose tissue in humans. Participants will complete two testing days, one before and one after their treatment period of approx. one year. On the testing days, identification of brown fat activity will be performed using cooling and infrared thermography. In addition, resting metabolic rate and a glucose tolerance test will be performed. Since presence of active brown adipose tissue in humans is inversely related to obesity, total and visceral fat mass, plasma glucose levels, presence of cardiovascular disease and diabetes status, it is of great importance to investigate the molecular mechanisms for development of brown fat tissue and may lead to discovery of novel strategies to counteract obesity and obesity related disorders.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta
- •Wiek powyżej 18 lat
- •Potwierdzona histologicznie choroba nowotworowa piersi
- •Brak wcześniejszego leczenia przed operacją
- •Pozytywny recepter estrogenowy (>1%)
- •Obecność brązowej tkanki tłuszczowej aktywowanej chłodem (zmiana temperatury >1°C)
- •HER2 dodatnia choroba nowotworowa piersi (dla grupy HER2+) lub HER2 ujemna (dla grupy kontrolnej)
- •Zaplanowane leczenie chemioterapią i lekami hormonalnymi
✗ Disqualifies
- •Inny nowotwór (z wyjątkiem raka in situ i operacyjnie usuniętych ograniczonych raków skóry) aktywny w ciągu ostatnich 2 lat
- •Przerzuty raka piersi do innych organów
- •Zaburzenia metaboliczne takie jak cukrzyca (chyba że dobrze leczona)
- •Regularne stosowanie kortyzonu (poza stosowaniem podczas chemioterapii)
- •Ciąża
- •Niekontrolowane wysokie ciśnienie krwi (skurczowe >155 lub rozkurczowe >95)
- •Poważne zaburzenia rytmu serca
- •Nieleczona choroba wieńcowa lub dusznica bolesna
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 19, 2024
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Centre for Physical Activity Research (CFAS), Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Trial contact
Tora Ida Henriksen, MSc., Ph.D.
Christina Yfanti, MSc, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.